Short answer
Definium Therapeutics, Inc. (DFTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$51M
- +24.2% YoY · +67.9% QoQ
- EPS (diluted)
- −$0.27
- +64.0% YoY · +81.3% QoQ
Source: XBRL data from the Definium Therapeutics, Inc. (DFTX) Q3 2026 10-Q on SEC EDGAR. USD.
Definium Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product candidates commercialized
- Operating margin not applicable, operating loss $72.3M vs $45.7M YoY
- Best-performing program: DT120 GAD, external costs $14.7M vs $16.2M YoY
- Cash, equivalents and investments approximately $1.0B; operating cash use $148.4M for nine months
- Cash runway into 2030; R&D expenses expected to increase throughout 2026
Risk Factors
- No material changes to risk factors during the three months ended September 30, 2026
- Existing 2025 Form 10-K risks remain applicable to business condition, results of operations and cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Definium Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.